5 completed, 4 terminated, 1 active not recruiting, 1 withdrawn. 11 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Terminated 4, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
Follow linrodostat: new trials by email Literature Review of linrodostat trials Research Report on linrodostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment Nivolumab, BMS- 986205 - Endometrial Adenocarcinoma, Endometrial Carcinosarcoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2019-09-24 | 2026-10-16 |
| A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma Nivolumab, BMS-986205, Ipilimumab - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2019-09-06 | 2020-02-05 | |
| Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck Nivolumab, IDO1 Inhibitor BMS-986205, Therapeutic Conventional Surgery - Lip, Oral Cavity Squamous Cell Carcinoma | Phase 2 | Terminated | Thomas Jefferson University | 65 | 2019-04-09 | 2026-10-19 |
| A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors BMS-986205, Nivolumab - Advanced Cancer | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 12 | 2018-12-31 | 2022-02-28 |
| BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer IDO1 Inhibitor BMS-986205, Nivolumab - Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 1 / Phase 2 | Terminated | Edward Kim | 8 | 2018-10-16 | 2026-07-29 |
| A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder Nivolumab, BCG, BMS-986205 - Urinary Bladder Neoplasms | Phase 2 | Terminated | Bristol-Myers Squibb | 142 | 2018-08-02 | 2023-06-01 |
| An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Relatlimab, Nivolumab, BMS-986205 - Advanced Cancer | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 229 | 2018-05-30 | 2026-04-06 |
| A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma Nivolumab, Ipilimumab, Relatlimab - Advanced Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 182 | 2017-02-02 | 2022-12-19 |
| A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer Nivolumab, Ipilimumab, Relatlimab - Advanced Gastric Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 190 | 2016-11-29 | 2023-06-09 |
| An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer Nivolumab, Dasatinib, Relatlimab - Advanced Cancer | Phase 2 | Terminated | Bristol-Myers Squibb | 295 | 2016-05-09 | 2021-03-22 |
| An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread BMS-986205, Nivolumab, Ipilimumab - Advanced Cancer, Melanoma | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 627 | 2016-04-14 | 2023-08-28 |
Melanoma (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Laryngeal Diseases (1) · Lymphoid Interstitial Pneumonia (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Urinary Bladder Neoplasms (1)
Bristol-Myers Squibb (7) · Dana-Farber Cancer Institute (1) · Edward Kim (1) · Memorial Sloan Kettering Cancer Center (1) · Thomas Jefferson University (1)
United States (10) · Australia (6) · Italy (6) · Canada (5) · France (4) · Spain (4) · Switzerland (3) · Austria (2) · China (2) · Germany (2) · Israel (2) · Netherlands (2) · United Kingdom (2) · Argentina (1) · Brazil (1)
Adam Luginbuhl, MD (1) · Chrisann Kyi, MD (1) · Edward Kim, MD, PhD (1) · Elizabeth I Buchbinder, MD (1)
2016 (2), 2015 (1), 2017 (1), 2018 (1), P30CA093373 (1)